Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer

Table 2 Primary and secondary outcomes at three weeks after completion of chemotherapy

QoL scales	Weekly docetaxel	3-weekly docetaxel	F	P-value
	Adjusted mean (SE)	Adjusted mean (SE)
FACT
TOI	63.78 (1.66)	64.20 (1.68)	0.030	0.86
Physical	21.20 (0.73)	21.63 (0.74)	0.172	0.68
Social	22.79 (0.62)	23.23 (0.64)	0.241	0.63
Emotional	19.21 (0.51)	19.32 (0.51)	0.024	0.88
Functional	19.80 (0.71)	18.48 (0.72)	1.691	0.20
Additional	22.85 (0.59)	24.02 (0.60)	1.921	0.17
RSCL
Physical	38.40 (1.14)	37.47 (1.14)	0.335	0.57
Psychological	12.79 (0.50)	11.76 (0.50)	2.057	0.16
HADS
Anxiety	4.53 (0.44)	4.26 (0.44)	0.196	0.66
Depression	4.12 (0.39)	3.14 (0.39)	3.237	0.08
MRS
Relaxation	88.59 (6.64)	104.49 (6.64)	2.708	0.10
Happiness	93.67 (6.29)	106.72 (6.29)	2.045	0.16
Energy	40.65 (6.12)	59.01 (6.12)	4.443	0.04
Clear-headedness	103.41 (5.90)	106.51 (5.90)	0.138	0.71
Easygoingness	94.63 (6.17)	94.37 (6.17)	0.001	0.98
Confidence	98.25 (6.07)	105.91 (6.07)	0.744	0.39
Total	548.27 (22.68)	637.64 (23.28)	7.101	0.01

Abbreviations: QoL, quality of life; SE, standard error; FACT, functional assessment of cancer therapy; TOI, trial outcome index; RSCL, Rotterdam symptom checklist; HADS, hospital anxiety and depression scale; MRS, mood rating scale.

ISSN: 1471-2407